Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice

J Alzheimers Dis. 2010;20(4):1201-13. doi: 10.3233/JAD-2010-100117.

Abstract

Intrahippocampal injections of aggregated amyloid-beta (Abeta)1-42 in rats result in memory impairment and in reduction of hippocampal 5-HT2A receptor levels. In order to investigate how changes in 5-HT2A levels and functionality relate to the progressive accumulation of Abeta protein, we studied 5-HT2A receptor regulation in double transgenic AbetaPPswe/PS1dE9 mice which display excess production of Abeta and age-dependent increase in amyloid plaques. Three different age-groups, 4-month-old, 8- month-old, and 11-month-old were included in the study. [3H]-MDL100907, [3H]-escitalopram, and [11C]-PIB autoradiography was performed for measuring 5-HT2A receptor, serotonin transporter (SERT), and Abeta plaque levels in medial prefrontal cortex (mPFC), prefrontal cortex (PFC), frontoparietal cortex (FPC), dorsal and ventral hippocampus, and somatosensory cortex. To investigate 5-HT2A receptor functionality, animals were treated with the 5-HT2A receptor agonist DOI and head-twitch response (HTR) subsequently recorded. Expression level of the immediate early gene c-fos was measured by in situ hybridization. We found that the age-related increase in Abeta plaque burden was accompanied by a significant decrease in 5-HT2A receptor binding in mPFC in the 11-month-old group. The changes in 5-HT2A receptor binding correlated negatively with [11C]-PIB binding and were not accompanied by decreases in SERT binding. Correspondingly, 11-month-old transgenic mice showed diminished DOI-induced HTR and reduced increase in expression of c-fos mRNA in mPFC and FPC. These observations point towards a direct association between Abeta accumulation and changes in 5-HT2A receptor expression that is independent of upstream changes in the serotonergic system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / physiology
  • Amphetamines / pharmacology
  • Amyloid beta-Protein Precursor / biosynthesis*
  • Amyloid beta-Protein Precursor / genetics*
  • Aniline Compounds / pharmacokinetics
  • Animals
  • Autoradiography
  • Citalopram / pharmacokinetics
  • Data Interpretation, Statistical
  • Fluorobenzenes / pharmacokinetics
  • Genes, fos / genetics
  • Head Movements / drug effects
  • Humans
  • In Situ Hybridization
  • Indicators and Reagents
  • Male
  • Mice
  • Mice, Transgenic
  • Piperidines / pharmacokinetics
  • Plaque, Amyloid / pathology*
  • Receptor, Serotonin, 5-HT2A / genetics*
  • Receptor, Serotonin, 5-HT2A / physiology*
  • Selective Serotonin Reuptake Inhibitors / pharmacokinetics
  • Serotonin Antagonists / pharmacokinetics
  • Serotonin Receptor Agonists / pharmacology
  • Thiazoles / pharmacokinetics

Substances

  • 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
  • Amphetamines
  • Amyloid beta-Protein Precursor
  • Aniline Compounds
  • Fluorobenzenes
  • Indicators and Reagents
  • Piperidines
  • Receptor, Serotonin, 5-HT2A
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Thiazoles
  • Citalopram
  • volinanserin
  • 4-iodo-2,5-dimethoxyphenylisopropylamine